5 hrs ago
Dr. Reddy’s Launches NIVORZ Cancer Biosimilar in India
Dr. Reddy’s Laboratories has introduced a new cancer medicine in India called NIVORZ.
It is a biosimilar version of nivolumab, an existing treatment that helps the immune system fight cancer.
The medicine was made at the company’s facility in Hyderabad.
Indian authorities approved it for 12 different cancer uses.
Researchers studied it in 288 patients from India and Russia.
The company said NIVORZ worked similarly to the original medicine in effectiveness, safety and other measures.
It comes in single-use containers and is given through an intravenous infusion.
Dr. Reddy’s says the launch may help more patients afford immunotherapy.
The company also said the launch expands its cancer-drug business.
Dr. Reddy’s Laboratories has launched NIVORZ, a biosimilar to nivolumab, in India.
The launch marks the company’s entry into biosimilar immuno-oncology in the country.
NIVORZ was developed and manufactured at the company’s biologics facility in Bachupally, Hyderabad.
The drug was approved for 12 cancer indications after a clinical programme involving 288 patients in India and Russia.
Dr. Reddy’s said the biosimilar could improve access to immunotherapy, whose Indian market was valued at about ₹3,900 crore in 2025.
- Who
- Dr. Reddy’s Laboratories, including its biologics and global generics leaders, launched NIVORZ.
- What
- The company launched NIVORZ, a nivolumab biosimilar approved for 12 cancer indications.
- Where
- India; NIVORZ was developed and manufactured at Bachupally, Hyderabad.
- When
- The launch was announced on Tuesday, with the report published September 15, 2026.
- Why
- Dr. Reddy’s said the launch expands its immuno-oncology business and aims to improve access to biologic cancer treatments.
Key facts
- Drug
- NIVORZ, a biosimilar to nivolumab and the reference drug Opdivo.
- Approval
- Approved by the Drugs Controller General of India for 12 indications.
- Clinical programme
- Included 288 patients: 252 from India and 36 from Russia.
- Manufacturing site
- Dr. Reddy’s biologics facility in Bachupally, Hyderabad.
- Administration
- Given through intravenous infusion in 40 mg/4 mL, 100 mg/10 mL and 240 mg/24 mL single-dose vials.
- Market size
- India’s immuno-oncology market was estimated at about ₹3,900 crore in 2025.
- Approved uses
- Includes cancers such as non-small cell lung cancer, renal cell carcinoma, melanoma, colorectal cancer, oesophageal cancer and gastric cancer.
Quotes
Sridevi Khambhampaty
Global head of biologics at Dr Reddy’s Laboratories
“As access to immunotherapy continues to be a challenge for many patients, we remain committed to improving access to high-quality treatment options through affordable biosimilars such as Nivroz”
thehindubusinessline.com
“The launch of NIVORZ marks an important milestone for our biologics business”
CNBC TV 18
Sources
Related news
Cipla, Qilu Partner on Keytruda Biosimilar for US Patients
Mounjaro Becomes India’s Top-Selling Drug Amid GLP-1 Shift
Novartis India Buys Minipress Brands for ₹1,250 Crore
India’s Smart Cancer Drug RK-251 Targets Tumor Cells
Investors Increase Bets on India’s Growing Supplements Sector
